Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
J&J plots filings after psoriasis drug clears phase 3 test
Johnson & Johnson's once-daily oral IL-23 inhibitor icotrokinra met efficacy objectives in phase 3 ICONIC-LEAD trial for moderate to severe plaque psoriasis, with 74.1% achieving clear or almost clear skin at week 24. The drug showed similar safety profiles to placebo and could offer a patient-friendly alternative to injectable biologics. J&J plans to submit data to regulators and compete with Bristol-Myers Squibb's TYK2 inhibitor Sotyktu.
Prostate cancer: Three drug trials to watch
Prostate cancer is the most common cancer among men in the US, with a need for more therapies for later-stage patients. Several candidates are under investigation, including Candel Therapeutics' oncolytic virus therapy, Johnson & Johnson's Akeega (PARP inhibitor + abiraterone acetate), and Pfizer's mevrometostat (EZH2 inhibitor). These therapies aim to improve treatment options for prostate cancer patients, especially those with advanced or resistant disease.
Related Clinical Trials:
Johnson & Johnson appoints CIO to lead business technology strategy
Johnson & Johnson appointed Chris Della Rocca as SVP, CIO of corporate business technology, overseeing tech strategy for corporate functions. Della Rocca, with nearly 20 years at J&J, will report to EVP and CIO Jim Swanson. The company integrates AI into operations and product development to advance healthcare.
J&J's New Psoriasis Drug Shows Breakthrough Results in Phase 3 Trial, 74% Success Rate
Icotrokinra (JNJ-2113) met co-primary endpoints in moderate to severe plaque psoriasis, with 74% achieving clear or almost clear skin at week 24. Results to be presented at medical congresses.
Related Clinical Trials:
FDA grants breakthrough therapy status to nipocalimab for Sjögren's disease
Johnson & Johnson's nipocalimab granted FDA breakthrough therapy designation for treating moderate to severe Sjögren’s disease, based on Phase 2 DAHLIAS trial results showing a 70% reduction in systemic disease activity at 24 weeks with the 15 mg/kg dose. Nipocalimab, designed to block FcRn and reduce IgGs, is the first antibody therapy to show positive Phase 2 results in Sjögren’s patients, with no current disease-modifying treatments available.
Related Clinical Trials:
CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC
The CHMP recommended the MA for lazertinib in combination with amivantamab to treat advanced NSCLC with EGFR ex19del or exon 21 L858R mutations. The combination could establish a new first-line standard of care, potentially delaying disease progression and improving outcomes. The recommendation is based on the MARIPOSA study, which showed a 30% reduction in disease progression or death compared to osimertinib.
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval
Syndax Pharmaceuticals' drug Revuforj, a menin inhibitor, received FDA approval for treating acute leukemia with KMT2A translocation, offering a new treatment option for patients with poor prognoses. The drug, priced at $39,500/month, showed promising results in a Phase 1/2 study, with 21.2% achieving complete remission. Revuforj carries a black box warning for differentiation syndrome risk.
AI Can Transform Drug Development, New ITIF Report Finds
AI can halve drug development times by boosting efficiency across the entire pipeline, from discovery to manufacturing, according to ITIF. AI tools accelerate drug target identification, optimize clinical trial designs, and enhance manufacturing efficiency, making therapies more accessible. ITIF recommends supportive policies for AI's full potential, including privacy-enhancing data sharing, public research funding, risk-based regulatory standards, and workforce training.
The PFA race is heating up. Here's where the market stands after J&J's approval.
Competition in the pulsed field ablation (PFA) market intensifies with Johnson & Johnson's Varipulse, Boston Scientific's Farapulse Nav, and Medtronic's Affera. These devices treat atrial fibrillation (AFib) with integrated mapping, offering faster and safer procedures compared to traditional methods. PFA is rapidly becoming the standard of care, with Boston Scientific and Medtronic seeing strong adoption. Abbott trails with its Volt device expected to file for FDA approval next year.
© Copyright 2024. All Rights Reserved by MedPath